# Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer

> **NCT01963182** · PHASE2 · COMPLETED · sponsor: **Centre Jean Perrin** · enrollment: 47 (actual)

## Conditions studied

- First Line Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01963182
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2019-12
- **Final completion:** 2019-12-09
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01963182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01963182, "Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01963182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*